cians continue to rec-
ognize early stages of
the disease. Patients
are also becoming
more aware of the
following minimally
invasive treatment
options that can
reduce the burden of
a daily drop regimen.
They might even
show up at your facil-
ity to have them
done.
• Sustained-
release medications.
IOP-lowering thera-
pies can be delivered
with injections, drug-
eluting implants
placed in the trabecu-
lar meshwork, drug-
impregnated punctal
plugs and conjuncti-
val polymer rings.
Some say they could
supplant topical
drops as the pre-
ferred non-surgical
treatment method for
Only the OMNI™ Surgical System
allows you to target the three
points of resistance in the
conventional outflow pathway -
trabecular meshwork, Schlemm's
canal and distal collector
channels - with one sophisticated,
implant-free device.
One MIGS device.
Two implant-free procedures.
Three points of resistance.
For more patients.
©2019 Sight Sciences.
All rights reserved.
06158.A
Indications for use: The OMNI™ Surgical System is a manually
operated device for delivery of small amounts of viscoelastic fluid,
for example Healon® or HealonGV® from Abbott Medical Optics
(AMO), Amvisc® from Bausch & Lomb, or PROVISC® from Alcon,
during ophthalmic surgery. It is also indicated to cut trabecular
meshwork tissue during trabeculotomy procedures.
O
M
N
I
S
U
R
G
I
C
A
L
.
C
O
M
